Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy

References

• King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302:643 - 6; http://dx.doi.org/10.1126/science.1088759; PMID: 14576434
   PubMed Web of Science ®Google Scholar
• Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336:1401 - 8; http://dx.doi.org/10.1056/NEJM199705153362001; PMID: 9145676
   PubMed Web of Science ®Google Scholar
• van der Kolk DM, de Bock GH, Leegte BK, Schaapveld M, Mourits MJ, de Vries J, van der Hout AH, Oosterwijk JC. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat 2010; 124:643 - 51; http://dx.doi.org/10.1007/s10549-010-0805-3; PMID: 20204502
   PubMed Web of Science ®Google Scholar
• Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, Froster UG, Schlehe B, Bechtold A, Arnold N, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009; 27:5887 - 92; http://dx.doi.org/10.1200/JCO.2008.19.9430; PMID: 19858402
   PubMed Web of Science ®Google Scholar
• Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72:1117 - 30; http://dx.doi.org/10.1086/375033; PMID: 12677558
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van’t Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, et al, Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346:1616 - 22; http://dx.doi.org/10.1056/NEJMoa012158; PMID: 12023993
   PubMed Web of Science ®Google Scholar
• Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck T, Neuhausen SL, Ghadirian P, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005; 23:7491 - 6; http://dx.doi.org/10.1200/JCO.2004.00.7138; PMID: 16234515
   PubMed Web of Science ®Google Scholar
• Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, et al, Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006; 296:185 - 92; http://dx.doi.org/10.1001/jama.296.2.185; PMID: 16835424
   PubMed Web of Science ®Google Scholar
• Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346:1609 - 15; http://dx.doi.org/10.1056/NEJMoa020119; PMID: 12023992
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999; 91:1475 - 9; http://dx.doi.org/10.1093/jnci/91.17.1475; PMID: 10469748
   PubMed Web of Science ®Google Scholar
• Consortium BCL, Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997; 349:1505 - 10; http://dx.doi.org/10.1016/S0140-6736(96)10109-4; PMID: 9167459
   PubMed Web of Science ®Google Scholar
• Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M, et al, HEBON, EMBRACE, GEMO Study Collaborators, kConFab Investigators, SWE-BRCA Collaborators, Consortium of Investigators of Modifiers of BRCA1/2. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012; 21:134 - 47; http://dx.doi.org/10.1158/1055-9965.EPI-11-0775; PMID: 22144499
   PubMed Web of Science ®Google Scholar
• Tilanus-Linthorst MM, Obdeijn IM, Hop WC, Causer PA, Leach MO, Warner E, Pointon L, Hill K, Klijn JG, Warren RM, et al. BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Cancer Res 2007; 13:7357 - 62; http://dx.doi.org/10.1158/1078-0432.CCR-07-0689; PMID: 18094417
   PubMed Web of Science ®Google Scholar
• Eerola H, Heikkilä P, Tamminen A, Aittomäki K, Blomqvist C, Nevanlinna H. Relationship of patients’ age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 2005; 7:R465 - 9; http://dx.doi.org/10.1186/bcr1025; PMID: 15987451
   PubMedGoogle Scholar
• Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, Tung N, Olopade OI, Weber BL, McLennan J, et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 2004; 10:2029 - 34; http://dx.doi.org/10.1158/1078-0432.CCR-03-1061; PMID: 15041722
   PubMed Web of Science ®Google Scholar
• Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 304:967 - 75; http://dx.doi.org/10.1001/jama.2010.1237; PMID: 20810374
   PubMed Web of Science ®Google Scholar
• Phillips KA, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, Frost D, Easton DF, Ellis S, Friedlander ML, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2013; 31:3091 - 9; http://dx.doi.org/10.1200/JCO.2012.47.8313; PMID: 23918944
   PubMed Web of Science ®Google Scholar
• Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M, Kim-Sing C, Olsson H, Ainsworth P, Eisen A, et al, Hereditary Breast Cancer Clinical Study Group. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 2006; 118:2281 - 4; http://dx.doi.org/10.1002/ijc.21536; PMID: 16331614
   PubMed Web of Science ®Google Scholar
• Li W, Xiao C, Vonderhaar BK, Deng CX. A role of estrogen/ERalpha signaling in BRCA1-associated tissue-specific tumor formation. Oncogene 2007; 26:7204 - 12; http://dx.doi.org/10.1038/sj.onc.1210527; PMID: 17496925
   PubMed Web of Science ®Google Scholar
• Jones LP, Tilli MT, Assefnia S, Torre K, Halama ED, Parrish A, Rosen EM, Furth PA. Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer. Oncogene 2008; 27:794 - 802; http://dx.doi.org/10.1038/sj.onc.1210674; PMID: 17653086
   PubMed Web of Science ®Google Scholar
• Cerne JZ, Zong L, Jelinek J, Hilsenbeck SG, Wang T, Oesterreich S, McGuire SE. BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients. Breast Cancer Res Treat 2012; 135:135 - 43; http://dx.doi.org/10.1007/s10549-012-2117-2; PMID: 22706629
   PubMed Web of Science ®Google Scholar
• Péqueux C, Raymond-Letron I, Blacher S, Boudou F, Adlanmerini M, Fouque MJ, Rochaix P, Noël A, Foidart JM, Krust A, et al. Stromal estrogen receptor-α promotes tumor growth by normalizing an increased angiogenesis. Cancer Res 2012; 72:3010 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-11-3768; PMID: 22523036
   PubMed Web of Science ®Google Scholar
• Kotsopoulos J, Lubinski J, Lynch HT, Kim-Sing C, Neuhausen S, Demsky R, Foulkes WD, Ghadirian P, Tung N, Ainsworth P, et al. Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2012; 21:1089 - 96; http://dx.doi.org/10.1158/1055-9965.EPI-12-0201; PMID: 22564871
   PubMed Web of Science ®Google Scholar
• Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998; 90:1138 - 45; http://dx.doi.org/10.1093/jnci/90.15.1138; PMID: 9701363
   PubMed Web of Science ®Google Scholar
• Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC, Jensen RA. Growth retardation and tumour inhibition by BRCA1. Nat Genet 1996; 12:298 - 302; http://dx.doi.org/10.1038/ng0396-298; PMID: 8589721
   PubMed Web of Science ®Google Scholar
• Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995; 9:444 - 50; http://dx.doi.org/10.1038/ng0495-444; PMID: 7795653
   PubMed Web of Science ®Google Scholar
• Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV, Vermorken JB, Janssen EA. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 2005; 23:5993 - 6001; http://dx.doi.org/10.1200/JCO.2005.05.511; PMID: 16135467
   PubMed Web of Science ®Google Scholar
• Baak JP, Gudlaugsson E, Skaland I, Guo LH, Klos J, Lende TH, Søiland H, Janssen EA, Zur Hausen A. Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers. Breast Cancer Res Treat 2009; 115:241 - 54; http://dx.doi.org/10.1007/s10549-008-0126-y; PMID: 18665447
   PubMed Web of Science ®Google Scholar
• Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002; 20:2310 - 8; http://dx.doi.org/10.1200/JCO.2002.09.023; PMID: 11981002
   PubMed Web of Science ®Google Scholar
• Osin P, Gusterson BA, Philp E, Waller J, Bartek J, Peto J, Crook T. Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers. Eur J Cancer 1998; 34:1683 - 6; http://dx.doi.org/10.1016/S0959-8049(98)00248-2; PMID: 9893652
   PubMed Web of Science ®Google Scholar
• Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR, Dowsett M. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995; 55:3331 - 8; PMID: 7614468
   PubMed Web of Science ®Google Scholar
• Fakkert IE, Mourits MJ, Jansen L, van der Kolk DM, Meijer K, Oosterwijk JC, van der Vegt B, Greuter MJ, de Bock GH. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers. Cancer Prev Res (Phila) 2012; 5:1291 - 7; http://dx.doi.org/10.1158/1940-6207.CAPR-12-0190; PMID: 23009828
   PubMed Web of Science ®Google Scholar
• Groenendijk RP, Bult P, Tewarie L, Peer PG, van der Sluis RF, Ruers TJ, Wobbes T. Screen-detected breast cancers have a lower mitotic activity index. Br J Cancer 2000; 82:381 - 4; PMID: 10646892
   PubMed Web of Science ®Google Scholar
• Peer PG, van Dijck JA, Hendriks JH, Holland R, Verbeek AL. Age-dependent growth rate of primary breast cancer. Cancer 1993; 71:3547 - 51; http://dx.doi.org/10.1002/1097-0142(19930601)71:11<3547::AID-CNCR2820711114>3.0.CO;2-C; PMID: 8490903
   PubMed Web of Science ®Google Scholar
• Retsky MW, Swartzendruber DE, Wardwell RH, Bame PD. Is Gompertzian or exponential kinetics a valid description of individual human cancer growth?. Med Hypotheses 1990; 33:95 - 106; http://dx.doi.org/10.1016/0306-9877(90)90186-I; PMID: 2259298
   PubMed Web of Science ®Google Scholar
• Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19:403 - 10; http://dx.doi.org/10.1111/j.1365-2559.1991.tb00229.x; PMID: 1757079
   PubMed Web of Science ®Google Scholar
• NABON. Breast Cancer Guideline [Internet]. Integraal Kankercentrum Nederland, 2012.
   Google Scholar